AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19603365 — intervention group
Group type: EXPERIMENTAL
Intervention: VTG
Number of subjects: 151
Study 19603365 — intervention group
Group type: COMPARATOR
Intervention: CG
Number of subjects: 151
Study 17498484 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Sanju Formula (YQSJF)
Number of subjects: 45
Study 17498484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 15136785 — intervention group
Group type: EXPERIMENTAL
Intervention: SRD5A1 polymorphisms
Number of subjects: 0
Study 15136785 — intervention group
Group type: COMPARATOR
Intervention: SRD5A2 polymorphisms
Number of subjects: 0
Study 11222787 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide 150 mg/d
Number of subjects: 279
Study 11222787 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide 300 mg/d
Number of subjects: 279
Study 11222787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 9932140 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised outpatient, hospital-based cardiac rehabilitation
Number of subjects: 3
Study 9932140 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation
Number of subjects: 3
Study 9932140 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3
Study 9932140 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 3
Study 7997845 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice combined with self monitoring of morning urine chloride concentration for 12 weeks
Number of subjects: 34
Study 7997845 — intervention group
Group type: COMPARATOR
Intervention: Dietary advice alone
Number of subjects: 34
Study 3412591 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (12.5 to 150 mg/d)
Number of subjects: 58
Study 3412591 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 58
Study 3412591 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam (0.5 to 6 mg/d)
Number of subjects: 58
Study 30402720 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster aspart
Number of subjects: 1215
Study 30402720 — intervention group
Group type: COMPARATOR
Intervention: IAsp
Number of subjects: 1215
Study 28922591 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5-20.0 mg/d)
Number of subjects: 161
Study 25593016 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75mg/m² IV every 21 days) with PX-866 (8mg PO daily)
Number of subjects: 85
Study 25593016 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75mg/m² IV every 21 days) without PX-866
Number of subjects: 85
Study 25593016 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel with PX-866
Number of subjects: 85
Study 25593016 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel without PX-866
Number of subjects: 85
Study 23412986 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 3 mg/kg/d for 3 months
Number of subjects: 100
Study 23412986 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 1 mg/kg for 3 months
Number of subjects: 100
Study 22321321 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone hydrochloride once daily for 16 weeks
Number of subjects: 236
Study 22321321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study 20183452 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted-Least-Squares (WLS) test statistic
Number of subjects: 0
Study 20183452 — intervention group
Group type: EXPERIMENTAL
Intervention: Logarithmic transformation of the WLS (LWLS) test statistic
Number of subjects: 0
Study 20183452 — intervention group
Group type: EXPERIMENTAL
Intervention: Squared-root transformation of the LWLS (SLWLS) test statistic
Number of subjects: 0
Study 20183452 — intervention group
Group type: EXPERIMENTAL
Intervention: Fisher's logarithmic transformation of LWLS (LLWLS) test statistic
Number of subjects: 0
Study 20183452 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-transformation of LWLS (ZLWLS) test statistic
Number of subjects: 0
Study 20183452 — intervention group
Group type: EXPERIMENTAL
Intervention: LWLS test statistic
Number of subjects: 0
Study 20183452 — intervention group
Group type: EXPERIMENTAL
Intervention: ZLWLS test statistic
Number of subjects: 0
Study 17124820 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Number of subjects: 0
Study 17124820 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 14745704 — intervention group
Group type: EXPERIMENTAL
Intervention: PIV3-cp45 vaccine
Number of subjects: 380
Study 14745704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study 11728891 — intervention group
Group type: EXPERIMENTAL
Intervention: One-session intervention based on the information‐motivation‐behavioral skills (IMB) model
Number of subjects: 78
Study 11728891 — intervention group
Group type: EXPERIMENTAL
Intervention: One-session information‐only intervention (INFO)
Number of subjects: 78
Study 11728891 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC) group
Number of subjects: 78
Study 9682687 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch-sensitive computer system (TSCS) with registered nurse liaison
Number of subjects: 507
Study 9682687 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch-sensitive computer system (TSCS) users
Number of subjects: 507
Study 7977116 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced silent ischemia (SI) in men
Number of subjects: 281
Study 7977116 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced silent ischemia (SI) in women
Number of subjects: 281
Study 7977116 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of SI by age in men
Number of subjects: 281
Study 7977116 — intervention group
Group type: COMPARATOR
Intervention: Comparison of men with SI to men with normal exercise ECG and thallium scan
Number of subjects: 281
Study 7977116 — intervention group
Group type: COMPARATOR
Intervention: Comparison of men with SI to men with overt CAD
Number of subjects: 281
Study 2920455 — intervention group
Group type: EXPERIMENTAL
Intervention: Canine fossa approach under local anaesthesia
Number of subjects: 0
Study 2920455 — intervention group
Group type: COMPARATOR
Intervention: Inferior meatus approach
Number of subjects: 0
Study 31347178 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertiveness training for 8 weeks
Number of subjects: 0
Study 31347178 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31527299 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned Pain Modulation (CPM) effect measured 6 weeks after hospital discharge
Number of subjects: 111
Study 31527299 — intervention group
Group type: COMPARATOR
Intervention: Non-randomized surgical treatment
Number of subjects: 111
Study 28454992 — intervention group
Group type: EXPERIMENTAL
Intervention: VarioGuide (VG)
Number of subjects: 53
Study 28454992 — intervention group
Group type: COMPARATOR
Intervention: Frame-Based (FB)
Number of subjects: 53
Study 25833969 — intervention group
Group type: EXPERIMENTAL
Intervention: High-egg diet (2 eggs/d for 6 d/wk)
Number of subjects: 140
Study 25833969 — intervention group
Group type: COMPARATOR
Intervention: Low-egg diet (<2 eggs/wk)
Number of subjects: 140
Study 25833969 — intervention group
Group type: EXPERIMENTAL
Intervention: High-egg diet
Number of subjects: 140
Study 25833969 — intervention group
Group type: COMPARATOR
Intervention: Low-egg diet
Number of subjects: 140
Study 25833969 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 140
Study 23692328 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily intake of 150-200 ml milk
Number of subjects: 0
Study 23692328 — intervention group
Group type: COMPARATOR
Intervention: Twice weekly intake of 150-200 ml milk
Number of subjects: 0
Study 23692328 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (daily and twice weekly)
Number of subjects: 0
Study 21502577 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopaxar (400 mg loading dose followed by 50, 100, or 200 mg daily)
Number of subjects: 603
Study 21502577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 603
Study 21502577 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopaxar (combined)
Number of subjects: 603
Study 19254122 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine porous bone mineral (BPBM) alone
Number of subjects: 45
Study 19254122 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine porous bone mineral (BPBM) plus collagen membrane (CM)
Number of subjects: 45
Study 19254122 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 45
Study 16627375 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle adjustments
Number of subjects: 3234
Study 16627375 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin therapy
Number of subjects: 3234
Study 16627375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3234
Study 15228506 — intervention group
Group type: EXPERIMENTAL
Intervention: Sighted Guide (SG) technique
Number of subjects: 40
Study 15228506 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Sighted Guide (NSG) technique
Number of subjects: 40
Study 15228506 — intervention group
Group type: EXPERIMENTAL
Intervention: String (ST) technique
Number of subjects: 40
Study 14679280 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Management of Childhood Illness (IMCI)
Number of subjects: 0
Study 14679280 — intervention group
Group type: COMPARATOR
Intervention: Comparison districts (non-IMCI)
Number of subjects: 0
Study 10880808 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Point Stimulation (MPS) technique
Number of subjects: 4
Study 10880808 — intervention group
Group type: EXPERIMENTAL
Intervention: Collision technique
Number of subjects: 4
Study 8715845 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary temperatures
Number of subjects: 173
Study 8715845 — intervention group
Group type: COMPARATOR
Intervention: Rectal temperatures
Number of subjects: 173
Study 8715845 — intervention group
Group type: COMPARATOR
Intervention: Oral temperatures
Number of subjects: 173
Study 1398956 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 5 x 10(8)‐CFU dose of live oral recombinant cholera vaccine CVD 103‐HgR
Number of subjects: 94
Study 1398956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 3987797 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimebutine 100 mg i.v.
Number of subjects: 10
Study 3987797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3358881 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg three times daily
Number of subjects: 17
Study 3358881 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 5 mg three times daily
Number of subjects: 17
Study 3358881 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 17
Study 3358881 — intervention group
Group type: COMPARATOR
Intervention: Pindolol
Number of subjects: 17
Study 31152023 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen-DI (doxorubicin 6×75 mg/m2/week; cisplatin 6×100 mg/m2/week every 2 weeks)
Number of subjects: 497
Study 31152023 — intervention group
Group type: COMPARATOR
Intervention: Regimen-C (doxorubicin 6×75 mg/m2/week; cisplatin 6×100 mg/m2/week every 3 weeks)
Number of subjects: 497
Study 28417910 — intervention group
Group type: EXPERIMENTAL
Intervention: L-CHO
Number of subjects: 10
Study 28417910 — intervention group
Group type: EXPERIMENTAL
Intervention: H-CHO
Number of subjects: 10
Study 28417910 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-PRO
Number of subjects: 10
Study 28417910 — intervention group
Group type: COMPARATOR
Intervention: PLA (Placebo control)
Number of subjects: 10
Study 26120745 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive-behavioral educational session
Number of subjects: 85
Study 26120745 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 85
Study 23235355 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 31
Study 23235355 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine 0.4 mg
Number of subjects: 31
Study 23235355 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 31
Study 23235355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 21692291 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal needling at Huantiao (GB 30)
Number of subjects: 60
Study 21692291 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture at Huantiao (GB 30), Yinmen (BL 37), Weizhong (BL 40), Yanglingquan (GB 34)
Number of subjects: 60
Study 19874586 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva biospecimens collected using Oragene(R) DNA Self‐Collection Kits
Number of subjects: 565
Study 19874586 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva volume
Number of subjects: 565
Study 19874586 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva clarity
Number of subjects: 565
Study 19874586 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA yield measured by UV
Number of subjects: 565
Study 19874586 — intervention group
Group type: EXPERIMENTAL
Intervention: % human DNA content
Number of subjects: 565
Study 19874586 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between saliva volume and DNA yield
Number of subjects: 565
Study 19874586 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping completion rate
Number of subjects: 565
Study 18044102 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic albuterol
Number of subjects: 12
Study 18044102 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol
Number of subjects: 12
Study 18044102 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 12
Study 14749569 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical autologous platelet‐enriched plasma combined with bovine collagen and thrombin (PCT)
Number of subjects: 78
Study 14749569 — intervention group
Group type: COMPARATOR
Intervention: Gelfoam/thrombin (G/T)
Number of subjects: 78
Study 11148527 — intervention group
Group type: EXPERIMENTAL
Intervention: pH‐dependent, enteric‐coated peppermint oil capsules
Number of subjects: 42
Study 11148527 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study 9631143 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH)
Number of subjects: 24
Study 9631143 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human insulin-like growth factor type 1 (rhIGF-1)
Number of subjects: 24
Study 9631143 — intervention group
Group type: EXPERIMENTAL
Intervention: combination of rhGH and rhIGF-1
Number of subjects: 24
Study 9631143 — intervention group
Group type: EXPERIMENTAL
Intervention: All therapies (rhGH, rhIGF-1, combination)
Number of subjects: 24
Study 7829435 — intervention group
Group type: COMPARATOR
Intervention: Dose schedule No.1 (group 2)
Number of subjects: 155
Study 7829435 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose schedule No.2 (group 3)
Number of subjects: 155
Study 7829435 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 1)
Number of subjects: 155
Study 3276281 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocarboxazid
Number of subjects: 130
Study 3276281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 30816056 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg/day
Number of subjects: 40
Study 30816056 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole 10 mg/day
Number of subjects: 40
Study 28075321 — intervention group
Group type: EXPERIMENTAL
Intervention: lifestyle and exercise intervention for 12 months
Number of subjects: 136
Study 28075321 — intervention group
Group type: COMPARATOR
Intervention: standard nephrological care
Number of subjects: 136
Study 25381337 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean mass-ratio standard
Number of subjects: 1170
Study 25381337 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-ratio standard
Number of subjects: 1170
Study 23406699 — intervention group
Group type: EXPERIMENTAL
Intervention: Peaked cap (CAP)
Number of subjects: 19
Study 23406699 — intervention group
Group type: COMPARATOR
Intervention: No peaked cap (NOCAP)
Number of subjects: 19
Study 20947174 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER (3-12 mg/day) as adjunctive therapy
Number of subjects: 300
Study 20947174 — intervention group
Group type: COMPARATOR
Intervention: Mood stabilizer monotherapy (valproate or lithium)
Number of subjects: 300
Study 19277690 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg misoprostol sublingually
Number of subjects: 200
Study 19277690 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg methyl‐ergometrine intramuscularly
Number of subjects: 200
Study 19277690 — intervention group
Group type: COMPARATOR
Intervention: 125 microg 15-methyl PGF2alpha intramuscularly
Number of subjects: 200
Study 16364165 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergic nasal challenge (grass pollen)
Number of subjects: 9
Study 16364165 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal challenge
Number of subjects: 9
Study 15472840 — intervention group
Group type: EXPERIMENTAL
Intervention: Live, attenuated, cold-adapted influenza vaccine (CAIV-T)
Number of subjects: 0
Study 11682400 — intervention group
Group type: EXPERIMENTAL
Intervention: tandospirone 10 mg (T10 group)
Number of subjects: 160
Study 11682400 — intervention group
Group type: EXPERIMENTAL
Intervention: tandospirone 30 mg (T30 group)
Number of subjects: 160
Study 11682400 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam 10 mg (D group)
Number of subjects: 160
Study 11682400 — intervention group
Group type: COMPARATOR
Intervention: placebo (P group)
Number of subjects: 160
Study 9135488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound scanning (US)
Number of subjects: 85
Study 9135488 — intervention group
Group type: COMPARATOR
Intervention: Palpation
Number of subjects: 85
Study 7896928 — intervention group
Group type: EXPERIMENTAL
Intervention: Rey Memory Test
Number of subjects: 28
Study 7896928 — intervention group
Group type: EXPERIMENTAL
Intervention: Rey Memory Test with a cut-off score of 9 items remembered
Number of subjects: 28
Study 7896928 — intervention group
Group type: EXPERIMENTAL
Intervention: Rey Memory Test with a cut-off of 3 rows remembered correctly
Number of subjects: 28
Study 3680600 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg nortriptyline test dose
Number of subjects: 18
Study 3680600 — intervention group
Group type: COMPARATOR
Intervention: 50 mg nortriptyline
Number of subjects: 18
Study 3680600 — intervention group
Group type: COMPARATOR
Intervention: 100 mg nortriptyline
Number of subjects: 18
Study 30857604 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavier sedation (modified OAA/S score 0-2)
Number of subjects: 200
Study 30857604 — intervention group
Group type: COMPARATOR
Intervention: Lighter sedation (modified OAA/S score 3-5)
Number of subjects: 200
Study 28085707 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline (100 mg twice a day)
Number of subjects: 50
Study 28085707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 28085707 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline
Number of subjects: 50
Study 25401779 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) and lifestyle advice for 6 months
Number of subjects: 109
Study 25401779 — intervention group
Group type: COMPARATOR
Intervention: Control group (lifestyle advice only)
Number of subjects: 109
Study 25401779 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 109
Study 24565240 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen with ilioinguinal-iliohypogastric nerve block (group DB)
Number of subjects: 61
Study 24565240 — intervention group
Group type: COMPARATOR
Intervention: Saline (group C)
Number of subjects: 61
Study 24565240 — intervention group
Group type: COMPARATOR
Intervention: Ilioinguinal-iliohypogastric nerve block (group B)
Number of subjects: 61
Study 21371281 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive ceftriaxone treatment (2 g, given every 24 h intravenously for four days)
Number of subjects: 3200
Study 21371281 — intervention group
Group type: COMPARATOR
Intervention: Standard care without preventive antibiotic treatment
Number of subjects: 3200
Study 21371281 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive ceftriaxone treatment
Number of subjects: 3200
Study 18422592 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol 1000 mg
Number of subjects: 70
Study 18422592 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline)
Number of subjects: 70
Study 17202203 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealed capsule irrigation (SCI) using distilled water for 2 minutes after phacoemulsification
Number of subjects: 17
Study 17202203 — intervention group
Group type: COMPARATOR
Intervention: Control group (fellow eye of each patient)
Number of subjects: 17
Study 15189176 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous epoetin alfa administration (group A)
Number of subjects: 81
Study 15189176 — intervention group
Group type: COMPARATOR
Intervention: Intravenous epoetin alfa administration (group B)
Number of subjects: 81
Study 15189176 — intervention group
Group type: COMPARATOR
Intervention: Intravenous epoetin alfa administration (group A after switch)
Number of subjects: 81
Study 15189176 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous epoetin alfa administration (group B after switch)
Number of subjects: 81
Study 11173981 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 260
Study 11173981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 8988824 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 0.15 mg.kg-1 followed by 0.1 mg.kg-1
Number of subjects: 32
Study 8988824 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium 0.9 mg.kg-1 followed by placebo
Number of subjects: 32
Study 8988824 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided dose mivacurium
Number of subjects: 32
Study 8988824 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium
Number of subjects: 32